Equillium Q2 net income $0.5M, revenue $13.9M; Ono itolizumab option decision by Oct 2024

Equillium, Inc.

2024-Q2 EPS reported -$0.06 revenue$24,542,000

Net income $0.5M ($0.01 EPS) vs net loss $3.3M in Q2 2023; revenue $13.9M (all from Ono collaboration), up from $9.1M.
Cash $33.3M, up $1.0M from Q1 2024; expects to fund operations for at least 12 months, adjusting spending if needed.
Ono option to acquire itolizumab rights decision by Oct 2024; if exercised, Equillium receives JPY 5B (~$35M) plus up to $101.4M milestones.
Phase 3 EQUATOR study (aGVHD) IDMC recommends proceed after positive interim review; no safety or futility concerns.
Positive topline data from Phase 1b EQUALISE (lupus nephritis) and Phase 2 EQ101 (alopecia areata); preparing Phase 2b study in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.